Eyeworld Daily News

2015 ASCRS San Diego Daily Monday

EyeWorld Today is the official daily of the ASCRS Symposium & Congress. Each issue provides comprehensive coverage editorial coverage of meeting presentations, events, and breaking news

Issue link: https://daily.eyeworld.org/i/498247

Contents of this Issue


Page 70 of 72

Please refer to pages 7 and 8 for important product information about the Alcon products described in this supplement. EW San Diego 2015 6 At 3 months postoperatively, 7.7% of eyes saw 20/10 or better without correction; 31.6% of eyes saw 20/12.5 or better; 68.8% of eyes saw 20/16 or better; 92.7% of eyes saw 20/20 or better; and 97.2% of eyes saw 20/25 or better. At 1 year, 15.7% of eyes saw 20/10 or better without correction; 34.4% of eyes saw 20/12.5 or better; 64.8% of eyes saw 20/16 or better; 92.6% of eyes saw 20/20 or better; and 96.5% of eyes saw 20/25 or better. Eyes treated with topography-guided treatment achieved an improvement in UCVA compared to preoperative BSCVA, with 29.6% of eyes gaining 1 or more lines of UCVA, and 89.9% of eyes seeing at least as well without correction postoperatively as they did with best spectacle correction preoperatively (Figure 1). The safety of topography-guided treatment was excellent, with only 5 single reports of loss of BSCVA of 2 or more lines at 1 month or later. One patient suffered bilater- al retinal detachments 6 months after topography-guided treatment. Complications were transient and did not result in significant loss of vision. In fact, there was a tendency toward an improvement in BSCVA after topography-guided treatment, compared to preoperatively, with a trend toward further improvement with time (Figure 2.) Most visual symptoms improved at 3 months after topography-guid- ed treatment compared to preopera- tive levels with habitual correction, reaching statistical significance for light sensitivity, difficulty driving at night, reading difficulty, and glare. Only double vision and foreign body sensation were reported as worse after 3 months, with minimal increases of 0.8% and 0.4%, respec- tively. The incidence and severity of visual symptoms continued to decline during the 12 months of the study (Figure 3). The Refractive Status and Vision Profile (RSVP) showed an improve- ment in all subscales and in the total composite score that is computed for each visit, including physical/social functioning, driving, visual symp- toms, optical problems, and prob- lems with corrective lenses that were evident at 3 months and continued to improve through 12 months postoperatively, compared to their vision while wearing glasses or con- tact lenses preoperatively. The only exception was glare at the 1-month visit, which showed a worsening that changed to improvement at 3 months and all subsequent visits. Published literature has indi- cated that a difference of 6 points or more on the composite score is a clinically significant change, 2 so the difference in composite score from baseline to each postoperative visit showed a clinically significant im- provement in the RSVP profile, with a mean improvement that is nearly 3 times the minimum threshold for clinically significant improvement at each postoperative visit, ranging from a change of –15.97 points at 3 months to a change of –16.39 points at 12 months. Most of these patients (98.4%) were satisfied with their outcomes and said they would have topography-guided treatment LASIK again. The results of this study exceed- ed our expectations. We thought that we would see good outcomes but did not think that topogra- phy-guided treatment on "normal" eyes without significant topographic abnormalities would exceed the out- comes we are accustomed to seeing with currently available treatments. To our surprise, we found excellent UCVA, significant improvements in BSCVA, and a reduction in visual symptoms. In fact, a majority of eyes had better postoperative UCVA than preoperative BSCVA. I feel that topography-guided treatment should be considered as a first- line treatment for the reduction of myopia and astigmatism within the approved FDA ranges. We have come a long way with corneal refractive surgery in the past 2 decades. The days when we had to warn patients that loss of BSCVA and visual aberrations might be the price they would have to pay for spectacle independence have passed. With topography-guided treatment, we should tell our patients there is an excellent likelihood that they will have better vision without correc- tion than they had preoperatively with correction and that the quality of their vision is likely to improve. We can now be confident that to- pography-guided treatment is likely to have a positive impact on quality of life of our patients. References 1. Summary of Safety and Effectiveness Data PMA P020050/S12 2. Schein, OD, et al. Patient outcomes of refractive surgery. The refractive status and vision profile. J Cataract Refract Surg. 2001; 27(5):665–73. Dr. Stulting is affiliated with the Stulting Research Center at Woolfson Eye Institute, Atlanta. He can be contacted at dstulting@ woolfsoneye.com. *Trademarks are property of their respective owners. continued from page 5 Figure 3: Visual symptoms: preop to 3 M, n=247 " Switching to the WaveLight refractive suite was an easy decision. A faster femtosecond laser means less chance of suction loss with apprehensive patients. Quick ablation times give patients a real sense of security. Every laser pulse is delivered exactly where it's supposed to be. Add to that a <1% enhancement rate in my hands, a wider range of treatable refractive errors, and fewer postop complaints from patients, it's easy to see why it is my choice for what is best for patients. " Charles Davis, DO Charles Davis, DO

Articles in this issue

Links on this page

Archives of this issue

view archives of Eyeworld Daily News - 2015 ASCRS San Diego Daily Monday